New Contract Research Organization Launches with Patient-Centered Approach

A new player has entered the competitive landscape of contract research organizations (CROs), promising to revolutionize clinical research with a focus on patient priorities and clinical realities. LyfeSci Research & Innovation, headquartered in a Chicago suburb, made its debut on October 21, 2025, under the leadership of founder and CEO Tapan Parikh, M.D.

Experienced Leadership at the Helm

Dr. Parikh, a board-certified adult and child psychiatrist with a 15-year research career spanning cardiology, oncology, neuroscience, and public health, brings a wealth of experience to the new venture. Joining him is William Gannon Jr., M.D., serving as LyfeSci's chief medical officer. Dr. Gannon's impressive background includes senior leadership roles at industry giants Quintiles (now IQVIA) and Pharmaceutical Product Development (PPD), which was acquired by Thermo Fisher Scientific for $17.4 billion in 2021.

Comprehensive Service Offerings

LyfeSci Research & Innovation aims to provide a full spectrum of services to the pharmaceutical and biotechnology industries. Their offerings encompass:

• Preclinical studies
• Investigational new drug (IND) application preparation
• Clinical trial management
• Biostatistics
• Pharmacovigilance
• Real-world data analysis

This comprehensive approach allows LyfeSci to support drug development from early-stage research through to post-marketing surveillance.

Patient-Centered Philosophy

At the core of LyfeSci's mission is a commitment to improving the clinical research experience for patients. Dr. Parikh emphasized this focus, stating, "Our goal is to revolutionize the clinical research experience by placing patients at the heart of everything we do." This patient-centric approach is designed to address site needs, which in turn reflect patient priorities and clinical realities.

Dr. Gannon elaborated on this philosophy, saying, "By evaluating new therapies through a real-world clinical lens, we design studies that truly matter to both patients and healthcare providers." The company's aim is to make clinical trials more accessible, practical for sites, valuable for sponsors, and ultimately transformative for patients.